en · de · es · pt
lab-handbook.peptides5388.com › Guide › Regulation, Testing, And Storage — Field Notes

Regulation, Testing, And Storage — Field Notes

By Editorial Desk · published 2025-09-02 · last reviewed 2025-09-19 · Guide

Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-09-19. Where a claim depends on a specific study, the study is described rather than over-claimed.

Regulation, Testing, and Storage

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

Background and Receptor Pharmacology

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

Sr9009 at a glance

PropertyValueNotes
Regulatory statusNot approved as a medicine in major jurisdictionsSold as a research chemical; legal status varies
Anti-doping statusProhibited by the World Anti-Doping AgencyListed under non-approved substances or related category
Typical analytical methodLC-MS/MSUsed for detection and confirmation in biological samples
Storage temperature−20 °C or lower for solidDesiccated and protected from light
Common solution solventsDMSO; ethanolAqueous solubility is limited

Analytical Detection and Storage

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Related pages on this site

Background and Mechanism

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

Background from the literature

Contamination with various chemicals have been identified. Some products contained trace amounts of the drugs tadalafil and rimonabant. The amount of either of these substances that is able to transfer from liquid to vapor phase is low. The nicotine impurities in the e-liquid varies greatly across companies. The levels of toxic chemicals in e-cigarette vapor is in some cases similar to that of nicotine replacement products. Tobacco-specific nitrosamines (TSNAs) such as nicotine-derived nitrosamine ketone (NNK) and N-Nitrosonornicotine (NNN) and tobacco-specific impurities have been found in the e-cigarette vapor at very low levels, comparable to amounts found in nicotine replacement products. A 2014 study that tested 12 e-cigarette devices found that most of them contained tobacco-specific nitrosamines in the e-cigarette vapor. In contrast, the one nicotine inhaler tested did not contain tobacco-specific nitrosamines. N-Nitrosoanabasine and N'-Nitrosoanatabine have been found in the e-cigarette vapor at lower levels than cigarette smoke. Tobacco-specific nitrosamines (TSNAs), nicotine-derived nitrosamine ketone (NNK), N-Nitrosonornicotine (NNN), and N′-nitrosoanatabine have been found in the e-cigarette vapor at different levels between different devices. Since e-liquid production is not rigorously regulated, some e-liquids can have amounts of impurities higher compared to limits for pharmaceutical-grade nicotine products.

== Demographics and geographical distribution == Bektashis are mainly found throughout Anatolia, the Balkans and among Ottoman-era Greek Muslim communities. According to a 2005 estimate by Dedebaba Reshat Bardhi, there are over seven million Bektashis worldwide, though more recent studies put the figure as high as 20 million. According to Albania's latest census in September 2023, Bekhtashis number slightly make up 9% of the Muslim population and 5% of the country's population. An additional 12.5 million Bektashis are estimated to live in Turkey. The term Alevi–Bektashi is used frequently in current Turkish religious discourse as an umbrella term for Alevism and Bektashism, despite their distinct origins and separate belief systems. Alevi/Bektashi is officially recognized through Ministry of Culture and Tourism under the 'Presidency of Alevi/Bektashi Culture'. There are also important Bektashi communities among the Albanian communities of North Macedonia and Kosovo, the most important being the Arabati Baba Teḱe in the city of Tetovo, which was until recently under the guidance of Baba Tahir Emini (1941–2006). Following the death of Baba Tahir Emini, the dedelik of Tirana appointed Baba Edmond Brahimaj (known as Baba Mondi), formerly head of the Turan Tekke of Korçë, to oversee the Harabati baba tekke. A splinter branch of the order has recently sprung up in the North Macedonian town of Kičevo which has ties to the Turkish Bektashi community under Haydar Ercan Dede rather than the order's headquarters in Tirana.

In the 13th and 14th centuries, some pilgrims to Canterbury journeyed via Billericay. Some of them may have spent the night in the town before crossing the river Thames at Tilbury; this may account for the large number of inns. The town's most notable historical episode was the Battle of Billericay during the Peasants' Revolt of 1381.

Sources: en.wikipedia.org

Reference notes

== Structure == Glutathione reductase from human erythrocytes is a homodimer consisting of 52kDa monomers, each containing 3 domains. GR exhibits single sheet, double layered topology where an anti-parallel beta-sheet is largely exposed to the solvent on one face while being covered by random coils on the other face. This includes and NADPH-binding Domain, FAD-binding domain(s) and a dimerization domain. Each monomer contains 478 residues and one FAD molecule. GR is a thermostable protein, retaining function up to 65 °C.

the model of pharmaceutical research and development, the expectations that companies and patient groups have about how risk and reward is shared between the industry and a publicly funded NHS, and in the arrangements for commissioning expensive new treatments.

=== Methods for peptide fragmentation === In low energy collision induced dissociation (CID), b- and y-ions are the main product ions. In addition, loss of ammonia (-17 Da) is observed in fragment with RKNQ amino acids in it. Loss of water (-18 Da) can be observed in fragment with STED amino acids in it. No satellite ions are shown in the spectra. In high energy CID, all different types of fragment ions can be observed but no losses of ammonia or water. In electron transfer dissociation (ETD) and electron capture dissociation (ECD), the predominant ions are c, y, z+1, z+2 and sometimes w ions. For post source decay (PSD) in MALDI, a, b, y-ions are most common product ions. Factors affecting fragmentation are the charge state (the higher charge state, the less energy is needed for fragmentation), mass of the peptide (the larger mass, the more energy is required), induced energy (higher energy leads to more fragmentation), primary amino acid sequence, mode of dissociation and collision gas.

Sources: en.wikipedia.org

Reference notes

Stanley Adams, Roche's World Product Manager in Basel, contacted the European Economic Community in 1973 with evidence that Roche had been breaking antitrust laws, engaging in price fixing and market sharing for vitamins with its competitors. Roche was fined accordingly, but a bungle on the part of the EEC allowed the company to discover that it was Adams who had blown the whistle. He was arrested for unauthorised disclosure — an offence under Swiss law — and imprisoned. His wife, having learnt that he might face decades in jail, committed suicide. In 1999 the firm pleaded guilty to participation in a worldwide conspiracy to raise and fix prices for vitamins sold in the US and globally. Hoffmann-La Roche paid $500 million in criminal fines to the United States.

Isotopomerism is analogous to constitutional isomerism or stereoisomerism of different elements in a structure. Depending on the formula and the symmetry of the structure, there might be several isotopomers of one isotopologue. For example, ethanol has the molecular formula C2H6O. Mono-deuterated ethanol, C2H5DO or C2H52HO, is an isotopologue of it. The structural formulas CH3−CH2−O−D and CH2D−CH2−O−H are two isotopomers of that isotopologue.

Effective dose at rest and adenosine-induced pharmacologic stress is equal to 0.019 mSv/MBq,; under exercise-induced stress, it is equal to 0.016 mSv/MBq. Whole-body effective dose is described as follows:

Serous acinar cells of the salivary glands, or more concisely, salivary serous cells, are cells that produce watery, enzyme-rich saliva. Together with salivary mucous cells, these cells secrete most of the fluid that becomes saliva. The term serous refers to the fact that the fluid produced is thin and watery like serum (blood plasma without clotting proteins).

Sources: en.wikipedia.org

Frequently asked questions

Is SR9009 legal?

Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.

How is SR9009 detected?

Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.

How should SR9009 be stored?

Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.

What is SR9009?

SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.

Network